3UGC
Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594
Summary for 3UGC
Entry DOI | 10.2210/pdb3ugc/pdb |
Descriptor | Tyrosine-protein kinase JAK2, 5-{[6-(acetylamino)pyrimidin-4-yl]oxy}-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-2,3-dihydro-1H-indole-1-carboxamide, MALONATE ION, ... (4 entities in total) |
Functional Keywords | small molecule inhibitor, atp binding, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Endomembrane system ; Peripheral membrane protein : O60674 |
Total number of polymer chains | 1 |
Total formula weight | 35202.15 |
Authors | Scheufler, C.,Tavares, G.A.,Manley, P.W.,Pissot-Soldermann, C.,Kroemer, M. (deposition date: 2011-11-02, release date: 2012-05-16, Last modification date: 2023-09-13) |
Primary citation | Andraos, R.,Qian, Z.,Bonenfant, D.,Rubert, J.,Vangrevelinghe, E.,Scheufler, C.,Marque, F.,Regnier, C.H.,De Pover, A.,Ryckelynck, H.,Bhagwat, N.,Koppikar, P.,Goel, A.,Wyder, L.,Tavares, G.,Baffert, F.,Pissot-Soldermann, C.,Manley, P.W.,Gaul, C.,Voshol, H.,Levine, R.L.,Sellers, W.R.,Hofmann, F.,Radimerski, T. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov, 2:512-523, 2012 Cited by PubMed: 22684457DOI: 10.1158/2159-8290.CD-11-0324 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.34 Å) |
Structure validation
Download full validation report